198 related articles for article (PubMed ID: 34358718)
1. National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States.
Kwong AJ; Ghaziani TT; Yao F; Sze D; Mannalithara A; Mehta N
Clin Gastroenterol Hepatol; 2022 May; 20(5):1142-1150.e4. PubMed ID: 34358718
[TBL] [Abstract][Full Text] [Related]
2. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.
Kulik L; Heimbach JK; Zaiem F; Almasri J; Prokop LJ; Wang Z; Murad MH; Mohammed K
Hepatology; 2018 Jan; 67(1):381-400. PubMed ID: 28859222
[TBL] [Abstract][Full Text] [Related]
3. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
[TBL] [Abstract][Full Text] [Related]
4. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
Huang AC; Mehta N; Dodge JL; Yao FY; Terrault NA
Hepatology; 2018 Aug; 68(2):449-461. PubMed ID: 29476694
[TBL] [Abstract][Full Text] [Related]
5. Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium.
DiNorcia J; Florman SS; Haydel B; Tabrizian P; Ruiz RM; Klintmalm GB; Senguttuvan S; Lee DD; Taner CB; Verna EC; Halazun KJ; Hoteit M; Levine MH; Chapman WC; Vachharajani N; Aucejo F; Nguyen MH; Melcher ML; Tevar AD; Humar A; Mobley C; Ghobrial M; Nydam TL; Amundsen B; Markmann JF; Berumen J; Hemming AW; Langnas AN; Carney CA; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
Ann Surg; 2020 Apr; 271(4):616-624. PubMed ID: 30870180
[TBL] [Abstract][Full Text] [Related]
6. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.
Agopian VG; Harlander-Locke MP; Ruiz RM; Klintmalm GB; Senguttuvan S; Florman SS; Haydel B; Hoteit M; Levine MH; Lee DD; Taner CB; Verna EC; Halazun KJ; Abdelmessih R; Tevar AD; Humar A; Aucejo F; Chapman WC; Vachharajani N; Nguyen MH; Melcher ML; Nydam TL; Mobley C; Ghobrial RM; Amundsen B; Markmann JF; Langnas AN; Carney CA; Berumen J; Hemming AW; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Busuttil RW
Ann Surg; 2017 Sep; 266(3):525-535. PubMed ID: 28654545
[TBL] [Abstract][Full Text] [Related]
7. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
Mehta N; Frenette C; Tabrizian P; Hoteit M; Guy J; Parikh N; Ghaziani TT; Dhanasekaran R; Dodge JL; Natarajan B; Holzner ML; Frankul L; Chan W; Fobar A; Florman S; Yao FY
Gastroenterology; 2021 Nov; 161(5):1502-1512. PubMed ID: 34331914
[TBL] [Abstract][Full Text] [Related]
8. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
[TBL] [Abstract][Full Text] [Related]
9. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation.
Lee DD; Samoylova M; Mehta N; Musto KR; Roberts JP; Yao FY; Harnois DM
Liver Transpl; 2019 Feb; 25(2):228-241. PubMed ID: 30198150
[TBL] [Abstract][Full Text] [Related]
10. Significant Reduction in Posttransplant Hepatocellular Carcinoma Recurrence in the Post 6-Mo Waiting Policy Era.
Mahmud N; Yagan L; Hoteit MA; Reddy KR; Abt PL; Abu-Gazala S
Transplantation; 2024 May; 108(5):1172-1178. PubMed ID: 37953481
[TBL] [Abstract][Full Text] [Related]
11. Role of Locoregional Therapy and Predictors for Dropout in Patients with Hepatocellular Carcinoma Listed for Liver Transplantation.
Sheth RA; Patel MS; Koottappillil B; Shah JA; Oklu R; Mueller P; Vagefi PA; Ganguli S
J Vasc Interv Radiol; 2015 Dec; 26(12):1761-8; quiz 1768. PubMed ID: 26419427
[TBL] [Abstract][Full Text] [Related]
12. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
[TBL] [Abstract][Full Text] [Related]
13. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
Mehta N; Dodge JL; Goel A; Roberts JP; Hirose R; Yao FY
Liver Transpl; 2013 Dec; 19(12):1343-53. PubMed ID: 24285611
[TBL] [Abstract][Full Text] [Related]
14. The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation.
Lai Q; Vitale A; Iesari S; Finkenstedt A; Mennini G; Onali S; Hoppe-Lotichius M; Manzia TM; Nicolini D; Avolio AW; Mrzljak A; Kocman B; Agnes S; Vivarelli M; Tisone G; Otto G; Tsochatzis E; Rossi M; Viveiros A; Ciccarelli O; Cillo U; Lerut J;
Liver Transpl; 2019 Jul; 25(7):1023-1033. PubMed ID: 31087772
[TBL] [Abstract][Full Text] [Related]
15. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy.
Firl DJ; Kimura S; McVey J; Hashimoto K; Yeh H; Miller CM; Markmann JF; Sasaki K; Aucejo FN
Hepatology; 2018 Oct; 68(4):1448-1458. PubMed ID: 29604231
[TBL] [Abstract][Full Text] [Related]
16. Independent prognostic factors for posttransplant survival in hepatocellular carcinoma patients undergoing liver transplantation.
Xing M; Kim HS
Cancer Med; 2017 Jan; 6(1):26-35. PubMed ID: 27860456
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated With Complete Pathologic Necrosis of Hepatocellular Carcinoma on Explant Evaluation After Locoregional Therapy: A National Analysis Using the UNOS Database.
Sarwar A; Bonder A; Hassan L; Malik MS; Novack V; Curry M; Ahmed M
AJR Am J Roentgenol; 2023 May; 220(5):727-735. PubMed ID: 36475810
[No Abstract] [Full Text] [Related]
18. Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies.
El-Gazzaz G; Sourianarayanane A; Menon KV; Sanabria J; Hashimoto K; Quintini C; Kelly D; Eghtesad B; Miller C; Fung J; Aucejo F
Hepatobiliary Pancreat Dis Int; 2013 Feb; 12(1):34-41. PubMed ID: 23392796
[TBL] [Abstract][Full Text] [Related]
19. Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States.
Young K; Liu B; Bhuket T; Younossi Z; Saab S; Ahmed A; Wong RJ
J Viral Hepat; 2017 Sep; 24(9):789-796. PubMed ID: 28273387
[TBL] [Abstract][Full Text] [Related]
20. Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma.
Xing M; Sakaria S; Dhanasekaran R; Parekh S; Spivey J; Knechtle SJ; Zhang D; Kim HS
Cardiovasc Intervent Radiol; 2017 Mar; 40(3):410-420. PubMed ID: 27900445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
